The updated 2021 WHO Classification of Tumors of the Central Nervous System has re-categorized IDH-mutant, grade 4 astrocytoma as a separate entity from glioblastoma; at the time patients were enrolled on this trial, this was not the case19. Here, IDH1 is linked to central nervous system cancer.